Look for the Union Label
This article was originally published in RPM Report
Executive Summary
The sales of Chrysler may mean more to pharma than new leases on company cars. If new management is serious about cutting costs, that could mean big changes to union contracts. The autoworker contracts have helped set the standards for public benefits for two decades--so any changes would have a big impact.
You may also be interested in...
Reinventing Pharmacy: The Bidding for Caremark is Just the Beginning
The battle between CVS and Express Scripts for ownership of Caremark has made little impact on drug-company executives. But there is an important implication for pricing in the Medicare Part D world: CVS wants to use Caremark to help it get higher payments for providing pharmacy services. But in the zero-sum game of reimbursement, any additional profits for chains will likely come from reduced prices on drugs.
Part D: A Big Chance for Small PBMs
Smaller PBMs are making bigger bets on the new Medicare drug market. Companies like RxAmerica, CVS/Pharmacare and Argus think their business models give them an edge over the "big three" pharmacy benefit managers in this major new market. If they are right, it could transform the entire US pharma sector.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.